WT1 and hematopoietic and lymphoid system neoplasm: In early studies of blood cancers, ACT using TCR-T cells specific for the Wilms’ tumor 1 (WT1) antigen were applied post-HSCT in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who were at high risk for relapse using TCR recognizing WT1-derived peptides presented by either HLA-A2 or HLA-A24 allotypes (10–12).